SCHEMBL4448943

SCHEMBL4448943

COc1ccc(S(=O)(=O)Cc2oc3ccccc3c2C)nn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.40
AKR1B1 P15121 1/20 0.39
MEN1 O00255 5/20 0.36
LMNA P02545 4/20 0.36
MAPT P10636 3/20 0.36
HTT P42858 2/20 0.36
ALDH1A1 P00352 2/20 0.36
HPGD P15428 1/20 0.36
ALOX15 P16050 1/20 0.36
CYP2C19 P33261 3/20 0.35
MKNK1 Q9BUB5 1/20 0.35
ADAMTS4 O75173 3/20 0.35
GPR55 Q9Y2T6 1/20 0.34
KDM4E B2RXH2 1/20 0.34
L3MBTL1 Q9Y468 3/20 0.34
MMP13 P45452 2/20 0.34
ADAMTS5 Q9UNA0 1/20 0.34
MMP2 P08253 1/20 0.33
MMP14 P50281 1/20 0.33
CYP2C9 P11712 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4452476 0.79 AKR1B1 (0.58) KMT2AAKR1B1MEN1LMNAMAPT
SCHEMBL4448901 0.76 AKR1B1 (0.65) AKR1B1
SCHEMBL4450670 0.72 KMT2A (0.39) KMT2AMEN1MAPTHTTALDH1A1
SCHEMBL4458342 0.70 AKR1B1 (0.43) KMT2AAKR1B1MEN1LMNAMAPT
SCHEMBL7030133 0.64 KCNH2 (0.48) KMT2AMEN1MAPTHTTALDH1A1
SCHEMBL10238814 0.64 CYP2C19 (0.49) KMT2AMEN1LMNAMAPTALDH1A1
SCHEMBL25766532 0.63 ALDH1A1 (0.41) KMT2AMEN1MAPTHTTALDH1A1
SCHEMBL4458458 0.63 AKR1B1 (0.64) KMT2AAKR1B1MEN1LMNAMAPT
SCHEMBL11365473 0.63 KCNH2 (0.47) KMT2AMEN1MAPTHTTALDH1A1
SCHEMBL4451859 0.63 AKR1B1 (0.61) KMT2AAKR1B1MEN1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572910-B2 Pyridazinone aldose reductase inhibitors PFIZER, INC. (US) 2009-08-11 US disclosed
EP-1491541-B1 Pyridazinone aldose reductase inhibitors PFIZER PROD INC (US) 2007-01-24 EP disclosed
EP-1491540-B1 Intermediates useful for the synthesis of pyridazinone aldose reductase inhibitors PFIZER PROD INC (US) 2006-12-13 EP disclosed
US-20050113381-A1 Pyridazinone aldose reductase inhibitors MYLARI BANAVARA L (US) 2005-05-26 US disclosed
US-6849629-B2 Heteroaromatic substituted sulfonyl or sulfoxide or thio-pyridazinone derivatives, useful for treating diabetic complications and cardiovascular disorders PFIZER, INC. (US) 2005-02-01 US disclosed
US-20050004124-A1 THERAPIES RELATING TO COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS MYLARI BANAVARA L (US) 2005-01-06 US disclosed
EP-1373259-B1 PYRIDAZINONE ALDOSE REDUCTASE INHIBITORS PFIZER PROD INC (US) 2004-12-29 EP disclosed
US-20040198740-A1 Therapies relating to combinations of aldose reductase inhibitors and cyclooxygenase-2 PFIZER INC 2004-10-07 US disclosed
EP-1392310-A1 COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS Pfizer Products Inc. (US) 2004-03-03 EP disclosed
EP-1373259-A1 PYRIDAZINONE ALDOSE REDUCTASE INHIBITORS Pfizer Products Inc. (US) 2004-01-02 EP disclosed
US-20030162784-A1 Pyridazinone aldose reductase inhibitors MYLARI BANAVARA L (US) 2003-08-28 US disclosed
US-6579879-B2 Pyridazinone aldose reductase inhibitors PFIZER INC 2003-06-17 US disclosed
WO-2002087584-A1 COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS PFIZER PRODUCTS INC. (US) 2002-11-07 WO disclosed
WO-2002079198-A1 PYRIDAZINONE ALDOSE REDUCTASE INHIBITORS PFIZER PRODUCTS INC. (US) 2002-10-10 WO disclosed
US-20020143017-A1 Pyridazinone aldose reductase inhibitors MYLARI BANAVARA L (US) 2002-10-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113381-A1 Pyridazinone aldose reductase inhibitors SLC5A1, ALDOA, AKR1B1 KMT2A 4357/4885AKR1B1 3/4885MEN1 3777/4885
US-20030162784-A1 Pyridazinone aldose reductase inhibitors SLC5A1, ALDOA, AKR1B1 KMT2A 4357/4885AKR1B1 3/4885MEN1 3777/4885
US-20020143017-A1 Pyridazinone aldose reductase inhibitors SLC5A1, AKR1B1, AKR1D1 KMT2A 4400/4885AKR1B1 2/4885MEN1 3535/4885
US-20050004124-A1 THERAPIES RELATING TO COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS ALDOA, AKR1B1, ALDH2 KMT2A 4265/4885AKR1B1 2/4885MEN1 4510/4885
US-20040198740-A1 Therapies relating to combinations of aldose reductase inhibitors and cyclooxygenase-2 ALDOA, ALDH2, AKR1B1 KMT2A 4276/4885AKR1B1 3/4885MEN1 4414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.